Poultry Mycoplasmosis: Vaccine Strategies and Disease Management

Introduction

Poultry mycoplasmosis, primarily caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), represents a major economic burden to the commercial poultry industry worldwide [1]. These bacterial pathogens are responsible for chronic respiratory disease, airsacculitis, synovitis, and egg production losses in chickens and turkeys [1, 2]. Infection with MG predisposes flocks to secondary bacterial infections, particularly colibacillosis, and exacerbates the severity of viral respiratory diseases such as Newcastle disease and avian influenza [1]. The control of poultry mycoplasmosis relies on a combination of biosecurity, eradication programs, antimicrobial therapy, and vaccination [2]. The development and application of effective poultry mycoplasma vaccines have become central to managing these infections in commercial settings where eradication is not economically feasible [1]. This article provides an exhaustive review of vaccine strategies for Mycoplasma gallisepticum and Mycoplasma synoviae, their efficacy, and integrated disease management approaches.

Etiology and Epidemiology

Mycoplasma gallisepticum is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [1]. Mycoplasma synoviae causes infectious synovitis and respiratory disease, often manifesting as subclinical airsacculitis in broilers [2]. Both species are small, wall-less bacteria of the class Mollicutes, characterized by their requirement for sterol-containing media and their tendency to establish persistent, often lifelong infections in the host [1]. Transmission occurs horizontally via direct contact, aerosol, and fomites, as well as vertically through the egg [3]. The establishment of MG-free breeder flocks through serological surveillance and eradication programs has been a cornerstone of control in many countries [2]. However, the prevalence of mycoplasmosis remains high in regions with multi-age farms and where biosecurity is difficult to enforce [1]. The clinical and subclinical impacts of MG and MS on growth rate, feed conversion, and egg production are well documented in standard poultry disease textbooks [1, 2]. For a detailed description of clinical signs and pathogenesis, readers are referred to the article on Mycoplasma gallisepticum in Poultry: Chronic Respiratory Disease and Control Strategies.

Vaccine Types for Poultry Mycoplasmosis

The development of poultry mycoplasma vaccines has centered on three main categories: live attenuated, inactivated (bacterin), and recombinant vector vaccines [1, 4]. Each type has distinct advantages and limitations regarding safety, efficacy, duration of immunity, and compatibility with eradication monitoring.

Live Attenuated Vaccines

Live attenuated vaccines are the most widely used option for MG control in commercial layers and breeders [1]. Three strains have been licensed and deployed internationally: the F strain, ts-11 strain, and 6/85 strain [4]. The F strain, originally isolated from a chicken with sinusitis, provides robust protection against respiratory challenge but retains moderate virulence and can spread to unvaccinated birds [1]. It also induces a strong serological response that complicates differentiation between vaccinated and naturally infected birds [3]. The ts-11 strain is a temperature-sensitive mutant that replicates primarily in the upper respiratory tract and produces minimal adverse reactions [1]. It is administered via eye drop and confers protection against respiratory lesions and egg production drops [4]. The 6/85 strain, also a mild vaccine, is typically delivered by coarse spray and offers lower immunogenicity but reduced potential for transmission [1]. All live MG vaccines require careful handling, cold chain maintenance, and appropriate timing of administration, usually between 4 and 10 weeks of age [2]. For MS, live attenuated vaccines based on the MS-H (Vaxsafe MS) strain have been developed and are administered similarly [4]. These vaccines reduce colonization and pathological changes in the respiratory tract and joints [1].

Inactivated (Bacterin) Vaccines

Inactivated or killed vaccines, usually prepared from whole-cell MG or MS cultures emulsified in oil adjuvants, are administered parenterally (subcutaneous or intramuscular) [1]. Bacterins induce a predominantly humoral immune response and are most frequently used in breeder flocks to reduce egg transmission and protect laying performance [2]. They require multiple doses (typically two to three) to achieve adequate protection, and the injection process can cause local reactions and handling stress [1]. Inactivated vaccines do not interfere with serological surveillance as reliably as some live vaccines, because the antibody response to bacterins can be distinguished from field infection by the absence of certain immunodominant antigens [3].

Recombinant and Vector Vaccines

Recombinant poultry mycoplasma vaccines have been constructed using fowl poxvirus and herpesvirus vectors expressing MG immunogenic proteins such as the cytadhesin molecule GapA (also known as MGC1) [1, 4]. These vectored vaccines aim to combine the safety of inactivated products with the cell-mediated immunity induced by live replicating vectors [4]. Studies have demonstrated that fowl poxvirus-vectored MG vaccines reduce airsac lesion scores and respiratory signs after challenge [1]. However, preexisting immunity to the vector virus (e.g., from prior fowl pox vaccination or natural exposure) can diminish the vaccine efficacy [4]. Recombinant vaccines for MS remain experimental but hold promise for broader protection [1]. The development of live recombinant Mycoplasma gallisepticum vaccines with defined genetic deletions (e.g., knockout of virulence genes) is an active area of research [4].

The following table summarizes the key attributes of each vaccine type.

Vaccine Efficacy and Limitations

The efficacy of poultry mycoplasma vaccines is evaluated by reduction in clinical signs, airsac lesion scores, and the prevention of egg production losses following experimental or field challenge [1]. Live vaccines, particularly ts-11 and MS-H, have demonstrated high levels of protection against homologous challenge and cross-protection against heterologous strains [4]. The F strain provides robust protection in layer flocks housed in multi-age facilities, but its ability to revert to virulence or cause disease in turkeys remains a concern [1]. Inactivated vaccines reduce vertical transmission and clinical signs but confer less robust protection against respiratory challenge compared to live vaccines [2]. The duration of immunity induced by live vaccines is generally prolonged, often lasting the productive life of a layer flock, whereas bacterins require booster vaccination every three to four months to maintain protective antibody titers [2].

A major limitation of current vaccines is their inability to entirely prevent infection or colonization; they primarily reduce disease severity and transmission [1]. Consequently, vaccination must be integrated with biosecurity, monitoring, and antimicrobial stewardship [2]. Interference with serological monitoring is a critical issue for producers in eradication programs. Some live vaccines, such as the F strain, induce antibodies that are indistinguishable from field infection using routine serological tests (e.g., rapid plate agglutination, ELISA) [3]. This has prompted the development of differentiating infected from vaccinated animals (DIVA) strategies, including recombinant vaccines and companion diagnostic tests targeting specific antigens [3, 4].

Disease Management Strategies

An integrated approach to poultry mycoplasmosis management combines vaccination with strict biosecurity, eradication of infected breeder flocks, and judicious use of antimicrobials [1]. The core principles are:

1. Biosecurity: Preventing introduction of MG and MS through all-in-all-out production, cleaning and disinfection, control of personnel and equipment movement, and placement of sentinel birds [2].
2. Eradication: Establishing MG-free and MS-free breeder flocks via serological testing and culling of positive birds [1]. This approach is the gold standard for primary breeding companies [2].
3. Medication: Antibiotics such as tylosin, tilmicosin, and tiamulin are used for treatment and control during outbreaks [1]. However, emerging antimicrobial resistance and withdrawal times for meat and eggs limit their use [2]. For a broader discussion of antibiotic resistance in poultry, see the article Antibiotic Resistance in Poultry: A Comprehensive Review of Bacterial Pathogens.
4. Vaccination: Used in commercial layers and breeders where eradication is impractical [1]. Vaccination reduces clinical signs and egg transmission but should not replace biosecurity [2].

Vaccination Programs

Vaccination programs are tailored to the production type (broiler, layer, breeder) and the mycoplasma species prevalent in the region [1]. For breeders, inactivated vaccines are often administered to reduce vertical transmission [2]. For commercial layers, live vaccines are favored for their ease of administration and long-lasting immunity [1]. Broilers are rarely vaccinated against mycoplasmosis unless the parent stock is infected; in such cases, the broilers may receive live vaccine early in life to reduce respiratory complications [4].

The following Mermaid diagram illustrates a decision tree for selecting a poultry mycoplasma vaccine strategy based on flock type and infection status.

flowchart TD
    A[Flock Type?], > B[Breeder]
    A, > C[Layer]
    A, > D[Broiler]
    B, > E[Is the flock MG/MS negative?]
    E, >|Yes| F[Maintain negative status: no vaccination, strict biosecurity]
    E, >|No| G[Administer inactivated bacterin, 2-3 doses before lay]
    C, > H[Is MG/MS endemic or challenge high?]
    H, >|Yes| I[Use live attenuated vaccine: ts-11 or MS-H at 4-10 weeks]
    H, >|No| J[No vaccination; monitor serology]
    D, > K[Are parent flocks infected?]
    K, >|Yes| L[Consider live vaccine at day-old or 7-14 days]
    K, >|No| M[No vaccination; rely on broiler resistance and biosecurity]

Vaccination timing must account for maternal antibody interference, especially in broilers [1]. Live vaccines are generally not given before two weeks of age in the presence of high maternal titers [2].

Differential Diagnosis and Surveillance

Accurate diagnosis of MG and MS infections relies on isolation, serology, and molecular methods. Isolation requires specialized media and is time-consuming [3]. Serological tests include rapid plate agglutination (RPA), hemagglutination inhibition (HI), and commercial ELISA kits [3]. The RPA test is sensitive but can yield false positives with certain vaccines (e.g., F strain) [3]. The HI test is more specific and is used as a confirmatory tool [3]. Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene or species-specific genes (e.g., mgc2 for MG) provide rapid and sensitive detection from tracheal swabs or tissues [3, 4]. Real-time quantitative PCR allows quantification of bacterial load [3]. For detailed diagnostic protocols, see the article Mycoplasma gallisepticum and Mycoplasma synoviae Infections in Chickens: Laboratory Diagnosis and Control Strategies.

Conclusion

Poultry mycoplasmosis remains a significant challenge for global poultry production, requiring multifaceted control strategies. Vaccination against Mycoplasma gallisepticum and Mycoplasma synoviae is an essential tool, with live attenuated vaccines offering practical and efficacious protection for commercial layers, while inactivated and recombinant vaccines play roles in breeder flocks and eradication programs. The choice of a specific poultry mycoplasma vaccine must consider the flock type, infection pressure, and the goals of the overall health program. Continued research into recombinant and DIVA-compatible vaccines will further enhance the ability to manage these pathogens while preserving the possibility of eventual eradication. Integration of vaccination with rigorous biosecurity and surveillance remains the cornerstone of sustainable disease management [1, 2].

References

[1] Swayne, D. E., Boulianne, M., Logue, C. M., McDougald, L. R., Nair, V., Suarez, D. L., & de Wit, S. (Eds.). (2020). Diseases of Poultry (14th ed.). Wiley-Blackwell.

[2] Merck & Co., Inc. (n.d.). The Merck Veterinary Manual (11th ed.). Kenilworth, NJ, USA.

[3] OIE (World Organisation for Animal Health). (2018). Manual of Diagnostic Tests for Avian Influenza and Mycoplasmosis. (OIE Terrestrial Manual, Chapter 2.3.5 for avian mycoplasmosis).

[4] Ley, D. H., & Yoder, H. W. (2013). Mycoplasma gallisepticum infection. In D. E. Swayne, J. R. Glisson, L. R. McDougald, L. K. Nolan, D. L. Suarez, & V. Nair (Eds.), Avian Medicine: Principles and Application (2nd ed., pp. 732–756). Wiley-Blackwell. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.